TY - JOUR
T1 - The economic impact of sudden cardiac arrest
AU - Paratz, Elizabeth D.
AU - Smith, Karen
AU - Ball, Jocasta
AU - van Heusden, Alexander
AU - Zentner, Dominica
AU - Parsons, Sarah
AU - Morgan, Natalie
AU - Thompson, Tina
AU - James, Paul
AU - Pflaumer, Andreas
AU - Semsarian, Christopher
AU - Stub, Dion
AU - Liew, Danny
AU - La Gerche, Andre
N1 - Funding Information:
The work of the EndUCD Registry is supported for the period 2019–2022 by funds from the EndUCD Foundation™ . EDP is supported by an NHMRC/NHF co-funded Postgraduate Scholarship, RACP JJ Billings Scholarship and PSA Cardiovascular Scholarship. CS is supported by an NHMRC Australia Practitioner Fellowship. ALG is supported by an NHF Future Leadership Fellowship and NHMRC Career Development Fellowship. DS is supported by an NHF Future Leadership Fellowship. DL declares grants from AbbVie , Amgen , AstraZeneca , Bristol-Myers Squibb , Pfizer , and Sanofi , and past participation in advisory boards and/or receipt of honoraria from AbbVie, Amgen, Astellas , AstraZeneca, Bristol-Myers Squibb, Edwards Lifesciences , Novartis , Pfizer, Sanofi, and Shire , outside the submitted work.
Funding Information:
The work of the EndUCD Registry is supported for the period 2019–2022 by funds from the EndUCD Foundation™. EDP is supported by an NHMRC/NHF co-funded Postgraduate Scholarship, RACP JJ Billings Scholarship and PSA Cardiovascular Scholarship. CS is supported by an NHMRC Australia Practitioner Fellowship. ALG is supported by an NHF Future Leadership Fellowship and NHMRC Career Development Fellowship. DS is supported by an NHF Future Leadership Fellowship. DL declares grants from AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Pfizer, and Sanofi, and past participation in advisory boards and/or receipt of honoraria from AbbVie, Amgen, Astellas, AstraZeneca, Bristol-Myers Squibb, Edwards Lifesciences, Novartis, Pfizer, Sanofi, and Shire, outside the submitted work.
Publisher Copyright:
© 2021
PY - 2021/6
Y1 - 2021/6
N2 - Background: There are 20,000 sudden cardiac arrests (SCAs) in Australia annually, with 90% case-fatality. Objective: The present study calculated both the health and economic impact of SCAs in Victoria, Australia. Methods: Data on all SCAs attended by Ambulance Victoria from July 2017 to June 2018 were collected regarding age, gender, and survival to hospital, discharge and 12 months. Pre-SCA employment status of all patients was modelled using age and gender-matched Australian economic data. A Markov state-transition model with a five-year horizon calculated health and economic impact in years of life lived (YLL), productivity-adjusted life years (PALYs) and gross domestic product (GDP) lost. A counterfactual Markov state-transition model assessed outcomes of an identical cohort of patients who did not experience SCA. All values were discounted by 5%. Results: In 12 months, 4637 people suffered SCAs in Victoria, of whom 1516 (32.7%) were working at the time. 695 patients (15.0%) survived to hospital, 325 (7.0%) to discharge, and 303 (6.5%) to 12 months. In five years following their SCA, the cohort lost 15,922 years of life and 2327 PALYs. Reduced productivity led to GDP losses of AUD$448 million (92.8% relative reduction). Extrapolated to the 20,000 SCAs occurring across all of Australia, total GDP losses approached AUD$2 billion. Conclusion: The health and economic burden of SCAs is high, predominantly underpinned by very high mortality. Annual national losses approach AUD$2 billion (USD$1.42 billion) and are comparable to productivity losses from all cancers combined. Prioritising research and state-of-the-art care for SCA patients appears economically sound.
AB - Background: There are 20,000 sudden cardiac arrests (SCAs) in Australia annually, with 90% case-fatality. Objective: The present study calculated both the health and economic impact of SCAs in Victoria, Australia. Methods: Data on all SCAs attended by Ambulance Victoria from July 2017 to June 2018 were collected regarding age, gender, and survival to hospital, discharge and 12 months. Pre-SCA employment status of all patients was modelled using age and gender-matched Australian economic data. A Markov state-transition model with a five-year horizon calculated health and economic impact in years of life lived (YLL), productivity-adjusted life years (PALYs) and gross domestic product (GDP) lost. A counterfactual Markov state-transition model assessed outcomes of an identical cohort of patients who did not experience SCA. All values were discounted by 5%. Results: In 12 months, 4637 people suffered SCAs in Victoria, of whom 1516 (32.7%) were working at the time. 695 patients (15.0%) survived to hospital, 325 (7.0%) to discharge, and 303 (6.5%) to 12 months. In five years following their SCA, the cohort lost 15,922 years of life and 2327 PALYs. Reduced productivity led to GDP losses of AUD$448 million (92.8% relative reduction). Extrapolated to the 20,000 SCAs occurring across all of Australia, total GDP losses approached AUD$2 billion. Conclusion: The health and economic burden of SCAs is high, predominantly underpinned by very high mortality. Annual national losses approach AUD$2 billion (USD$1.42 billion) and are comparable to productivity losses from all cancers combined. Prioritising research and state-of-the-art care for SCA patients appears economically sound.
KW - Economic analysis
KW - Epidemiology
KW - Productivity
KW - Sudden cardiac arrest
UR - http://www.scopus.com/inward/record.url?scp=85104682593&partnerID=8YFLogxK
U2 - 10.1016/j.resuscitation.2021.04.001
DO - 10.1016/j.resuscitation.2021.04.001
M3 - Article
C2 - 33865963
AN - SCOPUS:85104682593
SN - 0300-9572
VL - 163
SP - 49
EP - 56
JO - Resuscitation
JF - Resuscitation
ER -